Story thread · 4 reports / 3 sources

FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data

biopharmadive.com · 13dShare

Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.

First report: STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment — statnews.com, 14d